Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results

CitiusTech & Ventra Health unveil AI-powered revenue game-changer

The platform uses cutting-edge AI and automation to tackle the entire revenue cycle

Eyestem moves closer to blindness breakthrough with phase 2 trial green light

The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity

Parse Biosciences unveils integrated immune profiling in Trailmaker Platform

The new functionality complements Parse’s existing Evercode immune products

Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings

In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24

Truvian Health bags FDA clearance for CBC on TruVerus System

TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample

Bengaluru docs perform world’s first single-stage robotic heart bypass & prostate cancer surgery

Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report

The research shows 93% of global companies now cover weight-management drugs in their health insurance plans

Lupin receives highest ESG rating from CDP for climate change and water security

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability